<DOC>
	<DOCNO>NCT02816736</DOCNO>
	<brief_summary>The primary objective study determine whether , patient symptomatic , advanced heart failure due leave ventricular systolic dysfunction , treatment LCZ696 24 week improve Pro-B-type Natriuretic Peptide ( NT-proBNP ) level , reflect hemodynamic clinical status , compare treatment valsartan .</brief_summary>
	<brief_title>EntrestoTM ( LCZ696 ) In Advanced Heart Failure ( LIFE Study )</brief_title>
	<detailed_description>Patients advance heart failure reduce ejection fraction ( HFrEF ) extremely high morbidity mortality 1 year outcomes death hospitalization approximately 50 % . For advanced heart failure patient , evidence base medical treatment limited consensus guideline recommend consideration either cardiac transplant ventricular assist device , palliative care . The PARADIGM-HF trial show LCZ696 , consist neprilysin inhibitor sacubitril ARB valsartan , improve morbidity mortality patient chronic HFrEF comparison enalapril . However , limited experience advance heart failure patient gain patient enrolled trial . Because information effect sacubitril/valsartan patient NYHA class IV heart failure limit , updated 2016 ACC/AHA/HFSA guideline treatment heart failure yet endorse use sacubitril/valsartan patient NYHA class IV heart failure . Accordingly , experience need use , outcome LCZ696 patient unable tolerate target dose angiotensin-converting enzyme inhibitor ( ACEI ) / angiotensin receptor blocker ( ARB ) . This study randomize , double-blinded trial advance heart failure subject 1:1 randomization either LCZ696 ( sacubitril valsartan ) valsartan . Study drug administer double-dummy fashion , subject take active ( LCZ696 valsartan ) placebo . Approximately 400 subject randomize study . Subjects initial screen evaluation , include baseline laboratory test well assessment leave ventricular ( LV ) ejection fraction , time preliminary subject eligibility determine . The LV ejection fraction may obtain within prior 3 month 2-D echocardiogram , LV angiogram radionuclide scintigraphy . Willing subject meet entry criterion consent . Those meet entry criterion interested study participation enrol . Enrolled subject complete baseline assessment undergo run-in period 3-7 day LCZ696 50 mg ( equivalent Entresto™ 24/26 mg ) po BID prior randomization . For subject take ACEI , ACEI withhold ≥ 36 hour prior first dose LCZ696 . Subjects tolerate run-in period LCZ696 randomize 1:1 LCZ696 valsartan . Study treatment titrate target dose 200 mg LCZ696 ( equivalent Entresto™ 97/103 mg ) two 100 mg LCZ696 2 placebo tablet po BID valsartan 160 mg ( two 80 mg valsartan 2 placebo tablet ) po BID . * Randomized subject receive first dose study drug follow : - For subject previously take ACEI ARB , previously take ACEI ARB low dose* , subject eGFR &lt; 30 mL/min/1.73m² , start dose valsartan 40 mg po BID start dose LCZ696 50 mg po BID . - For subject take ARB great low dose† , start dose valsartan 80 mg po BID start dose LCZ696 100 mg po BID . - For subject take ACEI great low dose† , ACEI withhold ≥ 36 hour prior randomization . The start dose valsartan 80 mg po BID start dose LCZ696 100 mg po BID . Per package insert , valsartan compound Entresto™ bioavailable valsartan market formulation . The dose equivalence valsartan compound Entresto™ compare valsartan prepare alone ( Entresto™ dose = market valsartan dose ) follow : 26 mg=40 mg , 51 mg=80 mg , 103 mg=160 mg. † Low dose define 24 hour dose ≤ 10 mg lisinopril , ≤ 5 mg ramipril , ≤ 50 mg losartan , ≤ 10 mg olmesartan , dose equivalent . Dose adjustment perform every 2 week double dose LCZ696 valsartan target maximum dose . The dos LCZ696 50 mg ( one 50 mg active 1 placebo tablet ) , 100 mg ( one 100 mg active 1 placebo tablet ) 200 mg ( two 100 mg active 2 placebo tablet ) . These dos equivalent 24/26 mg , 49/51 mg , 97/103 mg commercial Entresto™ , respectively . The dos valsartan 40mg ( one 40 mg active 1 placebo tablet ) , 80 mg ( one 80 mg active 1 placebo tablet ) , 160 mg ( two 80 mg active 2 placebo tablet ) . The criterion double dose base systolic blood pressure ( SBP &gt; 90 mmHg require titration ) , change renal function ( maximum serum creatinine 2.0 mg/dL ) , absence symptom hypotension . For tolerate current dose study drug , dose down-titrated previous tolerate dose . Subjects return clinic follow-up visit 2 , 4 , 8 , 12 , 24 week randomization . Assessments follow-up visit include follow : medical history , review medication , physical examination New York Heart Association ( NYHA ) class assessment , Kansas City Cardiomyopathy Questionnaire ( KCCQ ) quality life questionnaire , local laboratory testing ( creatinine , Blood Urea Nitrogen ( BUN ) , electrolytes ) , Core laboratory test ( Cystatin C , NT-proBNP ) , adherence tolerance assessment , adverse event monitoring . Follow-up phone call make 10 , 16 , 20 , week randomization ass dose compliance , record occurrence applicable adverse event event interest , remind subject date time next in-person visit . A final phone visit conduct 2 week last dose study drug ( 26 week randomization ) ass clinical stability applicable adverse event . During consent process , subject ask interested donating sample data research purpose via biorepository and/or genetic study . Based site IRB preference , optional part study may incorporate main consent may separate consent Institutional Review Board ( IRB ) application .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . Advanced HFrEF define include ALL 1 . LVEF≤ 35 % document precede 3 month 2. estimate GFR 2060 mL/min/1.73m2 3 . NYHA class IV symptomatology majority previous month 4 . Minimum 3 month GDMT HF and/or intolerant therapy 2 . HF ≥1 symptom ( dyspnea , orthopnea , edema ) ≥ 1 sign congestion ( rales auscultation , ascites , peripheral edema , pulmonary vascular congestion chest radiography ) 3 . Systolic blood pressure ≥ 90 mmHg 4 . Serum NTproBNP ≥ 800 pg/mL OR BNP ≥ 250 pg/mL ( recent less 1 year old . ) 5 . Any one follow objective finding advance HF include : 1 . Inotropic therapy currently , ≥ 5 day past 6 month 2 . ≥ 1 hospitalization heart failure past 6 month ( include index hospitalization inpatient subject . ) 3 . LVEF ≤ 25 % ( within past 3 month ) 4 . PCW LVEDP ≥ 20 mmHg ( within past 3 month ) 5 . Peak VO2 &lt; 55 % predict peak VO2 ≤ 16 men ≤ 14 woman ( Respiratory Exchange Ratio ( RER ) ≥ 1.05 ) ( within past 12 month ) 6 . 6 min walk test distance &lt; 300 ( within past 3 month ) 7 . Estimated GFR &lt; 45 mL/min/1.73 m² measure simplified MDRD formula ( within past 12 month ) 8 . History intraaortic balloon pump placement within past 6 month 6 . Signed Informed Consent form 1 . Currently take Entresto™ 2 . History hypersensitivity intolerance Entresto™ , ACEI ARB well known suspect contraindication study drug . 3 . Age &lt; 18 year &gt; 85 year ; comorbid condition may cause death within 1 yr ( e.g . cancer , chronic obstructive pulmonary disease ( COPD ) ) ; recent history drug abuse . 4 . Symptomatic hypotension randomization . 5 . Serum potassium &gt; 5.5 mmol/L 6 . Severe liver dysfunction ( ChildsPugh Class C ) 7 . Acute coronary syndrome within 4 week define electrocardiographic ( ECG ) change biomarkers myocardial necrosis ( e.g . troponin ) appropriate clinical setting ( chest discomfort anginal equivalent ) 8 . Planned recent ( ≤ 4 week ) PCI , coronary artery bypass grafting , biventricular pace 9 . Currently hospitalize list 1A 1B transplant 10 . Current schedule LVAD implantation within 30 day study enrollment 11 . Active infection ( current use oral IV antimicrobial agent ) 12 . Primary hypertrophic infiltrative cardiomyopathy , acute myocarditis , constrictive pericarditis tamponade 13 . Complex congenital heart disease 14 . Concomitant use aliskiren patient diabetes renal impairment ( eGFR &lt; 60 mL/min/1.73 m² ) 15 . Known pregnancy anticipated pregnancy within next 6 month breastfeed mother 16 . Enrollment investigational clinical trial within 30 day prior screen 17 . Inability comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Valsartan</keyword>
	<keyword>Entresto</keyword>
</DOC>